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Drug-induced  respiratory  depression  (DIRD)  is a  common  problem  encountered  post-operatively  and
can  persist  for  days  after  surgery.  It is not  always  possible  to predict  the  timing  or  severity of  DIRD
due  to the  number  of contributing  factors.  A safe  and effective  respiratory  stimulant  could  improve
patient  care  by avoiding  the  use  of reversal  agents  (e.g.,  naloxone,  which  reverses  analgesia  as  well  as
respiratory  depression)  thereby  permitting  better  pain  management  by enabling  the  use  of  higher  dosesnesthesia
naleptic
pioid
ypoxia
of analgesics,  facilitate  weaning  from  prolonged  ventilation,  and  ameliorate  sleep-disordered  breathing
peri-operatively.  The  purpose  of  this  review  is to discuss  the current  pharmaceutical  armamentarium
of  drugs  (doxapram  and  almitrine)  that  are  licensed  for  use  in  humans  as respiratory  stimulants  and
that  could  be used  to reverse  drug-induced  respiratory  depression  in  the post-operative  period.  We  also
discuss  new  chemical  entities  (AMPAkines  and  GAL-021)  that  have  been  recently  evaluated  in Phase  1
clinical  trials and  where  the  initial  regulatory  registration  would  be  as  a respiratory  stimulant.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.. Introduction
Respiratory depression in the hospital setting is a common prob-
em encountered post-operatively and in the intensive care unit
Overdyk et al., 2007). In many instances, the respiratory depression
s an undesired consequence of administering drugs that sedate or
elieve pain. To illustrate, among postoperative patients receiving
pioids, the incidence of clinically signiﬁcant respiratory depres-
ion (respiratory acidosis and hypoxemia) requiring intervention
ccurs in approximately 2% of the surgical population (Overdyk
t al., 2007; Shapiro et al., 2005). Unfortunately, it is not always
ossible to predict the timing or severity of these events due to
he number of contributing factors, including age, sex, body-mass
ndex, presence of co-morbidities, and concomitant medications
dministered. On the other hand, some risk factors are very strong
redictors of respiratory complications post-operatively. For exam-
le, in bariatric patients the incidence of deleterious respiratory
vents post-operatively may  be as high as 100% (Overdyk et al.,
007).
     
 This paper is part of a special issue entitled “Clinical Challenges to Ventilatory
ontrol”, guest-edited by Dr. Gordon Mitchell, Dr. Jan-Marino Ramirez, Dr. Tracy
aker-Herman and Dr. Dr. David Paydarfar.
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Open access under CC BY-NC-SA lTypically, in the immediate post-operative period and while
in the post-anesthesia care unit, a patient’s ventilatory perfor-
mance is monitored intensively and respiratory depression can
be treated early with interventions such as verbal stimulation,
oxygen therapy, and positive airway pressure (i.e., CPAP). Occa-
sionally, profound respiratory depression requires reversal by
administering a selective antagonist of (e.g., naloxone or ﬂumaze-
nil) and/or decreasing subsequent doses of the depressant agent.
Although this approach may  improve respiratory function, seda-
tion and/or analgesia will be sub-optimal. If a safe and effective
respiratory stimulant drug were available to support breathing
post-operatively it is likely that pain control in some patients
would improve because analgesia could be used as the endpoint
for titration of an opioid rather than the magnitude of respiratory
depression it elicits.
For those patients who  remain intubated following surgery
(e.g., open chest procedures), mechanical ventilation avoids acute
post-operative respiratory depression, but creates the need for
weaning from mechanical ventilation and subsequent extubation,
and overall increases pulmonary complications. Early weaning and
extubation is associated with decreased post-operative morbidity
and mortality, however, not all patients are able to success-
fully wean from the ventilator and maintain adequate ventilation
after extubation, creating a clinical situation requiring an urgent
response, including re-intubation. In this scenario, acute ventila-
tory support with a ventilatory stimulant drug would likely provide
substantial patient beneﬁt and hasten patient return to an obser-
vational ward.
icense.
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Patients who are housed on usual patient ﬂoors for routine post-
perative care are at greatest risk for opioid-induced respiratory
epression from postoperative day 1 through day 5 (Overdyk et al.,
007; Reeder et al., 1992a,b; Taylor et al., 2005). In this setting, res-
iratory monitoring is typically limited. Progressive and ultimately
ife-threatening respiratory events may  go unrecognized until
igniﬁcant morbidity or mortality occurs. Thus, there is a need for
 respiratory stimulant beyond the post-anesthesia care unit. This
equirement could be met  by a drug that is formulated as: (1) both
n intravenous and oral preparation, or (2) an intravenous product
ith a long duration of effect.
Another important risk factor that is increasing in prevalence
s the co-morbidity of sleep-disordered breathing in the peri-
perative patient (Vasu et al., 2012). Unfortunately, the majority
f patients with sleep-disordered breathing remain undiagnosed
nd opioids and other respiratory depressants can exacerbate this
ondition (Yue and Guilleminault, 2010; Zutler and Holty, 2011).
urthermore, opioids may  have increased potency as analgesics in
ediatric and adult patients with nocturnal hypoxemia due to sleep
pnea (Brown et al., 2006; Doufas et al., 2013). This also translates
nto increased potency as respiratory depressants (Waters et al.,
002), creating a vicious circle of cause and effect. The importance
f sleep-disordered breathing peri-operatively dictates that any
rug developed for use as a respiratory stimulant needs to have
fﬁcacy in sleep-related breathing disturbances or, at the very least,
ot exacerbate the disorder.
The purpose of this review is to discuss the current pharmaceu-
ical armamentarium of drugs that are licensed for use in humans
s respiratory stimulants and that could be used to reverse drug-
nduced respiratory depression in the post-operative period. These
re currently restricted to doxapram (globally) and almitrine (select
ountries). Both drugs are believed to increase minute volume pri-
arily by inhibiting potassium channels within the carotid bodies.
hus, we will begin with a short description of the role of potas-
ium channels in carotid body chemoreception and the effects of
hese drugs at this molecular target. We will then review the past
nd present use of doxapram and almitrine and their limitations as
hemotherapeutics. We  will also brieﬂy discuss new chemical enti-
ies (AMPAkines and GAL-021) that have recently been evaluated
n Phase 1 clinical trials and where the initial regulatory registra-
ion would likely be as a respiratory stimulant in the post-operative
etting.
. Carotid body effects of current drugs
Doxapram and almitrine stimulate breathing by acting at the
evel of the carotid bodies. Transecting the carotid sinus nerve
locks the ventilatory effects of almitrine at all doses tested and
oxapram at normal clinical doses (de Backer et al., 1983; De Backer
t al., 1985; Laubie and Schmitt, 1980; Mitchell and Herbert, 1975;
ishino et al., 1982). At higher doses of doxapram, residual ventila-
ory stimulation persists in carotid and aortic denervated animals,
ndicating an additional site of action exists presumably within
he central nervous system (CNS) (Mitchell and Herbert, 1975;
ilkinson et al., 2010).
Both drugs are believed to increase carotid sinus nerve activ-
ty by co-opting a mechanism that contributes to endogenous
ypoxia sensing, namely inhibition of potassium channels on glo-
us  cells. A detailed description this mechanism can be found
lsewhere (Buckler, 2007; Peers et al., 2010). In brief, hypoxia
nhibits K+ channels on type I glomus cells causing depolarization
f the cell membrane and an inﬂux of Ca2+ through voltage-gated
a2+ channels. Calcium inﬂux triggers exocytosis of excitatory
eurotransmitters (e.g., ATP and acetylcholine), which in turn gen-
rate action potentials on nearby carotid sinus nerve afferent Neurobiology 189 (2013) 395– 402
terminals. Of the myriad oxygen-sensitive K+ channels that exist,
the primary types expressed on human glomus cells are a voltage-
dependent and Ca2+-activated channel (IKCa, also known as BK)
and a background leak channel (TWIK-related acid-sensitive K+
channel; TASK) (Fagerlund et al., 2010; Mkrtchian et al., 2012). The
main function of BK channels is to contribute to action potential
repolarization (Sah, 1996). Thus, drug-induced inhibition of this
channel increases action potential frequency. TASK channels are
outward leak currents that maintain resting membrane potential
(Mathie and Veale, 2007). Inhibition of these channels increases cell
excitability.
The effects of doxapram on BK channels were initially evalu-
ated using isolated neonatal rat glomus cells (Peers, 1991). In this
study, doxapram reversibly inhibited BK current (IC50 ∼ 5 M).  In a
later study using isolated rabbit carotid bodies, BK and TASK chan-
nel openers blocked the effects of doxapram on carotid sinus nerve
activity, suggesting that TASK channel inhibition also contribute
to the ventilatory effects of doxapram (Takahashi et al., 2005).
Indeed, doxapram inhibits current through cloned rat TASK chan-
nels expressed in oocytes (IC50 ∼ 400 nM for the TASK-1 subtype)
(Cotten et al., 2006). Given that therapeutic plasma concentra-
tion of doxapram is in the order of 4–5 M (see below), these
studies suggest that doxapram may  increase ventilatory drive
via inhibition of TASK channels and to a lesser extent the BK
channel.
The effects of almitrine on ionic currents from isolated rat
type 1 glomus cells have been reported (Lopez-Lopez et al.,
1998; Peers and O’Donnell, 1990). Almitrine inhibits BK currents
(IC50 ∼ 200 nM)  without altering voltage dependent K+, Na+, or cal-
cium currents. To our knowledge, the effect of almitrine on TASK
channels has not been tested.
3. Doxapram
3.1. General use
Doxapram was  ﬁrst identiﬁed as an analeptic agent with venti-
latory stimulant properties in the 1960s (Ward and Franko, 1962)
and was  used clinically for more than 40 years. In recent years, the
use of doxapram has declined considerably due to its side-effect
proﬁle that includes hypertension, anxiogenesis, and dyspnea (see
below). Doxapram (Dopram®) is still licensed for human use with
three primary indications (as per the Dopram package insert,
FDA.gov, 2013): (1) to stimulate respiration in the postoperative
patient and in patients with drug-induced post-anesthesia respi-
ratory depression or apnea, (2) to stimulate respiration, hasten
arousal, and return airway protective reﬂexes in patients with
respiratory and CNS depression due to drug overdosage, and (3)
to stimulate respiration in chronic pulmonary disease patients
with acute respiratory insufﬁciency. Doxapram also is used off-
label to decrease post-operative shivering in adults (Singh et al.,
1993), though this effect may  be minimal (Komatsu et al., 2005),
and apnea of prematurity in human neonates (Bairam et al.,
1992).
In veterinary medicine, doxapram is licensed for use in dogs,
cats and horses (Dopram-V®, Respiram®), and is used off-license in
other species. In animals, doxapram is primarily used to stimulate
respiration and speed awakening after general anesthesia, diag-
nose laryngeal paralysis, and initiate and stimulate respiration in
neonates following cesarean section or dystocia. However, in both
human and veterinary medicine, the need for an analeptic to hasten
arousal from anesthesia has declined considerably because of the
introduction of shorter-acting anesthetic agents (e.g., sevoﬂurane
and propofol).
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.2. Effects on breathing
.2.1. Effects on ventilation in drug-naïve subjects
Doxapram elicits respiratory stimulation as evidenced by
ncreased minute volume (V˙E) in a broad range of species (Bairam
t al., 1990; Bleul et al., 2010; Bleul and Bylang, 2012; Burki,
984; Calverley et al., 1983; Forster et al., 1976; Gregoretti and
leuvry, 1977; Khanna and Pleuvry, 1978; Murphy et al., 2010;
ilkinson et al., 2010). The increase in V˙E is predominantly due to
n increase in tidal volume (VT) with little effect on respiratory rate
RR), although a few studies report an increase in both. The effec-
ive blood concentration of doxapram in humans to increase V˙E is
.5–2 g/mL or ∼4–5 M (Calverley et al., 1983). This is similar to
ats (Galleon Pharmaceuticals, unpublished data) and is likely con-
erved across species. The major metabolite, keto-doxapram, is also
 ventilatory stimulant albeit with lower potency than the parent
ompound (Bairam et al., 1990).
.2.2. Effects on drug-induced hypoventilation
Many classes of drugs administered in the perio-operative
etting elicit alveolar hypoventilation. Doxapram can normalize
entilation by increasing ventilatory drive (i.e., a left shift in the CO2
esponse curve) (Ramamurthy et al., 1975; Randall et al., 1989), and
ncreasing CO2 (i.e., increased slope of the CO2 response curve) and
ypoxic (Lugliani et al., 1979) chemosensitivity. As long as a patient
an respond to chemoreceptor stimulation, doxapram should be
ble to increase V˙E in the presence of most drugs. Situations where
 patient may  not respond include severe CNS depression (e.g.,
ue to prolonged hypoxia, major drug overdose, or brainstem
njury), or an inability to increase activity of the respiratory mus-
les (e.g., in the presence of muscle relaxants or neuromuscular
isorders).
The class of drug most often associated with acute life-
hreatening respiratory depression is the opioids. Doxapram
iminishes the magnitude of opioid-induced hypoventilation
cross a range of species (Franko and Ward, 1971; Gasser, 1977;
older et al., 2012c; Gregoretti and Pleuvry, 1977; Hillidge, 1976;
hanna and Pleuvry, 1978; Ramamurthy et al., 1975) (Fig. 1). Nalox-
ne, a selective opioid receptor antagonist, reverses opioid-induced
espiratory depression but also removes analgesia which creates a
linical problem post-operatively. Doxapram does not interact with
pioid receptors and so analgesia is maintained.
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3.2.3. Effects on sleep-disordered breathing
Opioids and other respiratory depressants exacerbate preexist-
ing SDB in the perio-operative period (Vasu et al., 2012). The effect
of doxapram on the severity of obstructive sleep apnea (OSA) has
been evaluated in a small study using four subjects (Suratt et al.,
1986). Doxapram decreased the duration and severity of oxyhe-
moglobin desaturation events, with no effect on the number of
desaturations or time spent in NREM and REM sleep. Unfortunately,
doxapram also increased blood pressure, which is undesirable in
people with a disease known to cause hypertension. Although the
small sample size diminishes the ﬁndings of this study, the data
suggest that increasing respiratory drive chemically, presumably
via peripheral chemoreceptors, is a rational approach to treating
sleep disordered breathing (SDB) in the perio-operative setting.
3.3. Side effect proﬁle and toxicity
Nowadays, the primary limitation to more widespread use of
doxapram is its analeptic effect. Previously, this property was
desirable and used to hasten recovery from anesthesia. With use
of shorter-acting anesthetic agents, the need for stimulants has
diminished and the analeptic properties of doxapram are more
evident.
Doxapram is panicogenic and patients with a panic disorder
exhibit increased sensitivity to doxapram (Abelson et al., 1996a,b).
Panic disorders and abrupt increases in arousal can elicit hyper-
ventilation (Nardi et al., 2009). This relationship may explain
why residual ventilatory stimulation persists following doxapram
administration in carotid denervated/ablated animals and humans.
The pressor effects of doxapram have been recognized since
its initial use. In humans and dogs, the pressor effect in nor-
motensive individuals has been described as “slight” with a larger
sustained increase in blood pressure and cardiac output docu-
mented in hypotensive individuals (Kim et al., 1971; Stephen and
Talton, 1964). The mechanism whereby doxapram increases blood
pressure is unknown but may  be related to increased circulating
catecholamine levels during administration (Abelson et al., 1996b).
Doxapram increases heart rate in multiple species (Gay et al.,
1978; Jensen and Klemm, 1967; Wernette et al., 1986). The effects
on cardiac rhythm are less consistent (Hufﬁngton and Craythorne,
1966; Stephen and Talton, 1966). Doxapram prolongs the QT inter-
val on electrocardiograms in premature infants by an unknown
mechanism (Miyata et al., 2007). Drug-induced prolongation of the
0 5 10 15 20 25
100
150
200
250
300
morphine
drug infusion IV
*
* *
* *
* *
M
in
ut
e 
Vo
lu
m
e 
(m
l/m
in
)
Time (min)
Almitrine
n conscious rats. Minute volume was measured using whole-body plethysmography
rine (0.03 mg/kg/min) infusion. Morphine decreased minute volume approximately
 increased minute volume compared to vehicle controls. Graphs are modiﬁed from
ifferent to vehicle, p < 0.05. Values are means ± SEM.
3 logy &
Q
a
d
∼
r
i
m
t
(
d
(
3
(
i
p
t
e
s
r
e
i
P
a
m
a
e
t
b
0
o
b
d
c
G
l
d
r
4
4
r
m
H
i
d
d
m
1
1
I
P
i
p
t
r98 F.J. Golder et al. / Respiratory Physio
T interval may  be followed by potentially fatal arrhythmias, such
s Torsade de pointes.
In terms of severe life-threatening side effects, doxapram is
escribed as having a wide therapeutic window (in humans
20–40 fold) (Yost, 2006). At toxic single doses in animals (e.g.,
at LD50 = 72 mg/kg IV), the primary manifestation of toxicity
s CNS excitation including hyperactivity, tremors, tonic–clonic
ovements, and convulsions (Ward et al., 1968). Other symp-
oms include salivation, diarrhea, emesis, urination, and defecation
Ward et al., 1968). Doxapram is pro-convulsant but only at
oses much higher than those that evoke respiratory stimulation
Albertson et al., 1983).
.4. Stereo-selective effects of doxapram
Doxapram is racemic, and exists as a racemate with positive
+) and negative (−) enantiomers. There is considerable precedent
n the literature for the pharmacokinetic and pharmacodynamic
roperties of chiral drugs to be stereoselective. In these instances
he enantiomer possessing the desirable pharmacological prop-
rties is termed the eutomer, whereas the enantiomer lacking
uch properties is termed the distomer. We  hypothesized that the
espiratory stimulant properties of doxapram would be stereos-
lective and could be evaluated by chirally separating doxapram
nto its (+) enantiomer (GAL-054) and (−) enantiomer (GAL-053).
re-clinically we demonstrated that the (+) enantiomer, GAL-054,
nd not the (−) enantiomer, GAL-053, dose-dependently increased
inute volume when administered intravenously to drug naïve
nd opioid challenged rats and cynomolgus monkeys (Golder
t al., 2012a,b,c). Moreover, the deleterious side-effects of agita-
ion and seizures were restricted to GAL-053. There were minimal
ehavioral changes observed in rats and monkeys receiving GAL-
54. Thus, GAL-054 is the eutomer and GAL-053 the distomer
f doxapram. Unfortunately, in conscious rats GAL-054 increased
lood pressure approximately 15–20% above baseline values at
oses that were moderately respiratory stimulant. This effect was
onﬁrmed in a Phase 1 clinical trial evaluating the effects of
AL-054 in healthy volunteers (Galleon Pharmaceuticals, unpub-
ished data). Thus, the ventilatory stimulant and pressor effects of
oxapram cannot be separated by enantiomeric separation of the
acemate.
. Almitrine
.1. General use
Almitrine bismesylate was developed in the 1970s as a respi-
atory stimulant and ﬁrst commercialized in 1984 when it was
arketed under the product name VectarionTM (Tweney and
oward, 1987). In the past, almitrine was used intravenously
n the peri-operative setting for indications mirroring those for
oxapram, except not as an analeptic agent. Nowadays, albeit with
eclining frequency, almitrine is used chronically in the manage-
ent of chronic obstructive pulmonary disease (COPD) (Howard,
984; Smith et al., 1987; Tweney, 1987; Tweney and Howard,
987).
Almitrine has never been licensed for use in the United States.
n the European Union, availability is limited to France, Poland and
ortugal, where its primary indication is to improve oxygenation
n patients with chronic obstructive pulmonary disease. The Euro-
ean Medicines Agency has started a review of almitrine related
o adverse side effects including weight loss and peripheral neu-
opathies. Neurobiology 189 (2013) 395– 402
4.2. Effects on breathing
4.2.1. Effects on ventilation
Almitrine increases V˙E by increasing VT and/or RR across multi-
ple species (Dhillon and Barer, 1982; Flandrois and Guerin, 1980;
MacLeod et al., 1983; O’Halloran et al., 1996; Saupe et al., 1992;
Weese-Mayer et al., 1986, 1988). Almitrine is also efﬁcacious in the
face of an opioid challenge (Fig. 1) (Gruber et al., 2011). As discussed
above, the effects of almitrine on breathing are solely due to stim-
ulation of the peripheral chemoreceptors. Only one of almitrine’s
metabolites is active, but its potency as a respiratory stimulant is 5
times less than the parent compound (Campbell et al., 1983).
Almitrine improves post-operative indices of ventilation while
causing a mild decrease in blood pressure and no change in heart
rate or cardiac output (Laxenaire et al., 1986; Parotte et al., 1980),
contrasting with the pressor effects of doxapram. Almitrine’s pri-
mary use is as a respiratory stimulant in people with COPD.
Almitrine increases ventilation in patients with COPD, signiﬁcantly
improving blood gases and reducing the incidence of intubation
when compared to placebo controls (Lambropoulos et al., 1986).
4.2.2. Effects on breathing control at sub-stimulatory dose
At doses that do not increase V˙E, almitrine is still capable
of altering breathing control. This is best illustrated by a study
where the effects of gradually increasing the dose of almitrine
on hypoxic and hypercapnic sensitivity were evaluated in healthy
volunteers (Stanley et al., 1983). Almitrine dose-dependently
increased the slopes of the hypoxic (at >50 ng/mL) and hypercap-
nic (at >200 ng/mL) ventilatory responses without increasing V˙E
on room air. The authors also noted that the effects of almitrine
on chemosensitivity persisted despite plasma levels of the drug
declining below these thresholds. Small increases in V˙E (∼11%
above baseline) on room air were only observed when plasma
concentrations of almitrine exceeded approximately 250 ng/mL.
The ability of a carotid body stimulant to increase chemosensi-
tivity without an accompanying increase in V˙E during normoxia
may  reﬂect the limited role of the carotid body in modulating V˙E
during normoxic conditions. Thus, potentiation of carotid body
signaling in this scenario may  only be evident when an indi-
vidual is exposed to hypoxia and/or hypercapnia. The persistent
effect of almitrine on chemosensitivity despite waning plasma
levels may  be due to the presence of an active metabolite or
tissue binding of the drug within the peripheral chemorecep-
tors.
4.2.3. Effects on sleep disordered breathing
The effects of almitrine on sleep-disordered breathing in
humans have been evaluated with equivocal results (Hackett et al.,
1987; Mangin et al., 1983). Carotid body stimulation can stabilize
breathing and decrease apneic events during sleep by increas-
ing minute volume, thereby decreasing loop gain (Dempsey et al.,
2012). Loop gain is an engineering term that describes the sensi-
tivity of a variable system to perturbations. Loop gain comprises
controller gain (i.e., chemoreceptors) and plant gain (i.e., the
blood gas response to a change in ventilation). Almitrine has been
evaluated in an animal model where the inﬂuence of loop gain
on ventilatory stability is measured (Nakayama, 2002). Almitrine
decreased plant gain by stimulating ventilation and was  able to
protect against ventilator-induced central apneas and hypopneas.
Countering this stabilizing inﬂuence is the effect of almitrine on
hypoxic chemosensitivity (i.e., controller gain). Thus, almitrine can
increase controller gain, which would worsen sleep-disordered
breathing. The net effect of almitrine on sleep-disordered breath-
ing is likely to be dependent on the dose administered and the type
of patient in question.
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.2.4. Effects on ventilation–perfusion matching
Almitrine exerts beneﬁcial effects on pulmonary gas exchange
increased PaO2, and improved ventilation–perfusion ratios –
˙ A/V˙Q matching) without increasing V˙E (Barer et al., 1983; Hughes
t al., 1983, 1986; Melot et al., 1989). The mechanism responsible
or this effect is believed to be enhanced hypoxic pulmonary vaso-
onstriction (HPV). Almitrine improves V˙A/V˙Q matching in patients
ith COPD and increases pulmonary vascular resistance consistent
ith an effect on pulmonary vascular tone (Melot et al., 1983a,b).
PV is often depressed peri-operatively, so any new drug for this
etting that normalizes HPV would be highly desirable.
.3. Side effects and toxicity
Almitrine has a lower therapeutic dose and greater toxic dose
han doxapram (almitrine LD50 > 200 mg/kg in mice cf.  doxapram
D50 of 85 mg/kg in mice). Acutely, almitrine is generally well tol-
rated and safe in humans. Not surprisingly, increased awareness
f breathing and breathlessness are the most common side-effects
ollowing almitrine administration (Marsac, 1986; Naeije et al.,
981). Other side effects included headache, fatigue, insomnia,
alaise, ﬂushing, sweating, and postural dizziness (Naeije et al.,
981; Sergysels et al., 1980). Gastro-intestinal side effects included
ausea, abdominal discomfort, and diarrhea (MacLeod et al., 1983).
here are minimal changes in cardiovascular parameters except for
 mild increase in pulmonary artery pressure (Gluskowski et al.,
984, 1985; MacNee et al., 1986).
Almitrine is less tolerated when administered chronically.
ulti-year trials observed that patients receiving almitrine exhib-
ted signiﬁcant weight loss (>15%) that appeared to be anorectic
n nature (Ansquer, 1985; Ansquer et al., 1985; Gherardi et al.,
989). The most signiﬁcant and consistent side effect of chronic
more than 3 months) almitrine administration is peripheral neu-
opathy (Allen, 1988; Allen and Prowse, 1989; Bouche et al.,
989; Gherardi et al., 1989; Suggett et al., 1985). Further exam-
nation revealed that these patients showed axonal degradation
nd a decrease in the density of large myelinated ﬁbers. Mech-
nistic studies in animals identiﬁed the detriazinyl metabolite,
,4′-ﬂuorobenzhydrylpiperazine, the major almitrine metabolite
ormed in humans, as the probable cause of the evoked neuropa-
hy (Yamanaka et al., 1997). Thus, the use of almitrine is no longer
ecommended and is withdrawn or in regulatory review in many
ountries.
. New drugs in development as respiratory stimulants
There have been only a few new therapeutic agents devel-
ped that focus on respiratory control and even fewer have been
pproved for clinical use during the previous decades. One issue has
een poor translation of pre-clinical efﬁcacy into humans, as has
ccurred with the 5-HT1A and 5-HT4 receptors agonists, buspirone
nd mosapride (Lotsch et al., 2005; Oertel et al., 2007). This may  be
ore about the targets selected and not related to the use of rodents
s models for drug-induced respiratory depression, given the ini-
ial success and translatability of the AMPAkines and GAL-021 (see
elow).
The paucity of the new molecule entities in respiratory modula-
ion has resulted in the route to and benchmarks for registering
ew therapeutic products to be absent, outdated, or limited to
ingle pharmacological mechanism action. Thus, the methods for
etermining an early clinical Proof-of-Concept trial, including the
election of meaningful endpoints, will need to be developed for
ach potential indication that has strong negative predictive value
alanced by good positive predictive value for the therapeutic
tility of potential agents. Overall, much effort will be required Neurobiology 189 (2013) 395– 402 399
by health authorities, medical subspecialists, and drug develop-
ers to establish the pathway to new therapeutic entities marketing
approval and available for practitioners.
5.1. AMPAkines
AMPAkines are modulators of -amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptors and have been widely
explored for a variety of neuropsychiatric diseases including
schizophrenia and epilepsy (Chang et al., 2012; Russo et al.,
2012). Cognitive improvement has been the primary focus of most
research with this drug class (Hamlyn et al., 2009). Glutamate
acting via AMPA receptors is essential for maintaining respiratory
rhythmogenesis at the purported kernel of rhythm generation,
the preBötzinger complex in the hindbrain (Funk et al., 1993;
Greer et al., 1991). Thus, the rationale for the use of AMPAkines
to treat respiratory depression, in particular the type caused
primarily by a decrease in respiratory rate (e.g., opioid-induced
respiratory depression), is that positive allosteric modulators of
AMPA receptors would enhance respiratory rhythm.
Various AMPAkines (Cortex Pharmaceuticals, Inc.) have been
evaluated preclinically and clinically as respiratory stimulants. The
positive AMPA allosteric modulator CX546 reversed the ventila-
tory suppressive effects of fentanyl and phenobarbital in the rat
(Ren et al., 2006). A second AMPA receptor modulator, CX717,
has been tested pre-clinically and is also able to reverse the res-
piratory depressive effects of fentanyl, alcohol and pentobarbital
(Ren et al., 2009, 2012). CX717 also reverses opiate suppres-
sion of hypoglossal motor neurons (Lorier et al., 2010). In young
healthy subjects with a target alfentanil infusion concentration of
100 ng/mL (i.e., analgesic), CX717 prevented the fall in respiratory
rate vs. placebo (Oertel et al., 2010). However, in that study there
also was an interaction between alfentanil and CX717 with respect
to visual analog scale parameter “tiredness”, in that the participants
receiving CX717 reported increased tiredness compared to placebo
controls.
In humans, AMPAkines improved memory and information pro-
cessing in the healthy elderly (Wezenberg et al., 2007) and people
with schizophrenia (Goff et al., 2008). In a randomized, double-
blind, crossover study in sleep deprived young subjects, CX717
enhanced cognitive performance and alertness (Boyle et al., 2012).
Slow wave sleep was reduced and recovery sleep impaired. Thus,
the respiratory stimulatory effects of new AMPAkine molecules are
associated with stimulatory neuropsychiatric effects on arousal-
alertness state and cognitive performance. It remains possible
that dual effects of a single molecule on the neuropsychiatric and
respiratory systems will limit the utility of these compounds as
respiratory stimulants.
5.2. GAL-021
Agents that increase the drive to breathe by mimicking the
effects of acute hypoxia and/or hypercapnia at the level of the
peripheral chemoreceptors represent a rational approach toward
the development of therapeutics for breathing control disor-
ders that would beneﬁt from ventilatory stimulation. GAL-021
(Galleon Pharmaceuticals, Inc.), a BK channel blocker, is currently
in early clinical trials. GAL-021 is a new chemical entity designed
based on our understanding of the structure–activity relation-
ship and structure-tolerability limitations of almitrine. GAL-021
does not contain the ﬂuorinated piperazine ring, which causes
lipidosis in dorsal root ganglia in rat leading to peripheral neuropa-
thy and hindlimb dysfunction (Yamanaka et al., 1997). GAL-021
was extensively proﬁled in mice, rats, dogs, and cynomolgus
monkeys preclinically. In brief, GAL-021 stimulates ventilation
and attenuates opiate-induced respiratory depression but not
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orphine analgesia (Baby et al., 2012a; Golder et al., 2012d). GAL-
21 also reverses drug-induced respiratory depression elicited
y isoﬂurane, propofol, and midazolam (Galleon Pharmaceuti-
als, unpublished data). Ventilatory stimulation is accompanied by
nhanced carotid sinus nerve afferent and phrenic nerve efferent
ctivity (Baby et al., 2012b). Carotid sinus nerve transection almost
ompletely abolishes (∼85% reduction) GAL-021-induced respira-
ory stimulation (Baby et al., 2012b). The residual stimulation was
locked when the cervical vagi were transected in addition to the
arotid sinus nerve (Galleon Pharmaceuticals, unpublished data).
hus, some of the effects of GAL-021 on ventilation are mediated
rom other peripheral sites, most likely aortic chemoreceptors.
In healthy human subjects, GAL-021 administration caused
tatistically signiﬁcant increases in V˙E (AUE0–1 h) with reciprocal
uppression of ETCO2 during 1-h continuous infusions. The half-
aximal effect on V˙E and ETCO2 occurred rapidly (<10 min). Drug
oncentration rose rapidly during the infusion and declined rapidly
nitially with a distribution t1/2 of 30 min  and then more slowly with
 terminal t1/2 of 5–7 h. Thus, in humans GAL-021 has pharmaco-
ynamic and pharmacokinetic characteristics consistent with an
cute care medication. A Proof-of-Concept study using opioids in a
ypercapnic clamp setting is on-going in humans to determine the
linical utility of GAL-021 and to validate the BK channel as a ther-
peutic target. Further clinical development with phase 2 studies
n patients with post-operative respiratory depression is planned
or late 2014.
. Conclusions
It is clear that there is an unmet medical need for a safe
nd effective respiratory stimulant, especially during sleep, in
ost-operative patients receiving potent respiratory depressants.
oxapram and almitrine illustrates the potential utility of a carotid
ody stimulant in the treatment of drug-induced respiratory
epression, and possibly exacerbated sleep disordered breathing
n the perioperative setting. However, the widespread use of both
rugs is limited by their side effect proﬁles and toxicities. In the case
f doxapram, the primary limitation is in its pressor effects. But is
 pressor effect an inherent property of a carotid body stimulant?
n a recent review, Kumar suggests that the answer is no (Kumar,
009). He argues that although carotid body stimulation elicits a
tereotypical systemic response, which includes a range of cardio-
ascular reﬂexes, the precise cardiovascular effect depends upon
hether ventilation is, or is not, controlled. For example, if ventila-
ion can increase (e.g., a spontaneously breathing patient), carotid
ody stimulation typically increases heart rate and decreases sys-
emic vascular resistance with minimal changes or a slight decrease
n blood pressure. On the other hand, if ventilation is controlled (i.e.,
 patient on a ventilator), carotid body stimulation usually causes
radycardia, an increase in vascular resistance, and an associated
ressor effect. This dependence on whether breathing is sponta-
eous or controlled may  be related to the interplay of pulmonary
agal afferent feedback and PaCO2 on cardiovascular regulation. We
ave found that doxapram increases blood pressure in carotid body
enervated rats (Galleon Pharmaceuticals, unpublished data) sug-
esting that the pressor effects of this compound are due, at least
n part, to mechanisms outside of the carotid bodies. Thus, a selec-
ive carotid body stimulant with minimal central effects is likely
o be better tolerated in the post-operative setting than doxapram.
his is evident in the case of almitrine. Almitrine has a myriad of
ffects that would be beneﬁcial post-operatively, including rever-
al of drug-induced hypoventilation, enhanced chemosensitivity,
ecreased plant gain, and improved V˙A/V˙Q matching, but with min-
mal pressor effects. The primary limitation with almitrine is the
eripheral neuropathy following chronic use. GAL-021 does not Neurobiology 189 (2013) 395– 402
contain the ﬂuorinated piperazine ring associated with this toxicity
and appears to retain many of the desirable properties of almitrine.
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